Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

1. Be willing and able to provide written informed consent/assent for the trial;
2. Lung cancer patients whose pathological results confirmed is primary non-small cell lung cancer, stage III\~IV;
3. Patients received with ICIs treatment, including anti-PD-1 or anti-PD-L1 for at least two courses;

Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients